Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis

Journal of the Royal Society of Medicine, Supplement

Volumn 102, Issue SUPPL.1, 2009, Pages

  Jain, Mukta ^a   Thomson, Anne H ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; MOTAVIZUMAB; PALIVIZUMAB; PLACEBO; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; HUMAN; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; NASOPHARYNX; PNEUMOCOCCAL INFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; STREPTOCOCCUS PNEUMONIAE; VIRUS INFECTION; ADOLESCENT; ADULT; ARTICLE; BACTERIAL PNEUMONIA; CHILD; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; VIRUS PNEUMONIA;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 68949167590     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.2009.s19006     Document Type: Conference Paper

References (29)

1. Bell SC, Robinson PJ. Exacerbations in cystic fibrosis: 2. Prevention. Thorax 2007;62:723-732
2. Malfroot A, Adam G, Ciofu O, et al. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 2005;4:77-87 (Pubitemid 40867757)
3. Klinger CL, Snape MD, John T, et al. Immunogenicity Of DTaP-IPV-Hib And MenC Vaccines In The UK When AdministeredWith a 13-valent Pneumococcal Conjugate Vaccine. Abstract at ICAAC/IDSA meeting October 2008
4. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 2008;47:989-996
5. Lahiri T, Waltz DA. Preimmunization anti-pneumococcal antibody levels are protective in a majority of patients with cystic fibrosis. Pediatrics 2001;108:E62
6. Pollard AJ. Personal communication
7. Pickering Le. Report of the Committee on Infectious diseases: American Academy of Pediatrics. Pneumococcal Infections. Red Book 2000;452:458-459
8. Armstrong D, Grimwood K, Carlin JB, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998;26:371-379 (Pubitemid 29024978)
9. Collinson J, Nicholson KG, Cancio E, et al. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 1996;51:1115-1122 (Pubitemid 26402824)
10. Hament JM, Kimpen JL, Fleer A,Wolfs TF. Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS Immunol Med Microbiol 1999;26:189-195
11. Van Ewijk BE, Wolfs TF, Aerts PC, et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 2007;61:398-403
12. Wat D, Gelder C, Hibbitts S, et al. The role of respiratory viruses in cystic fibrosis. J Cyst Fibros 2008;7:320-328
13. Clifton IJ, Kastelik JA, Peckham DG, et al. Ten years of viral and non-bacterial serology in adults with cystic fibrosis. Epidemiol Infect 2008;136:128-134
14. Pribble CG, Black PG, Bosso JA, Turner RB. Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections. J Pediatr 1990;117:200-204 (Pubitemid 20238530)
15. Xu W, Zheng S, Goggans TM, et al. Cystic fibrosis and normal human airway epithelial cell response to influenza a viral infection. J Interferon Cytokine Res 2006;26:609-627 (Pubitemid 44689650)
16. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med 2006;355:31-40
17. Tan A, Bhalla P, Smyth R. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev 2000;(2):CD001753
18. Wat D, Gelder C, Hibbitts S, et al. Is there a role for influenza vaccination in cystic fibrosis?. J Cyst Fibros 2008;7:85-88
19. Murris-Espin M, Aubert M, Bosdure E, Dubus JC. Influenza vaccination coverage in patients with cystic fibrosis followed at 12 care centers in the Greater South Region of France for the season 2005/2006. Vaccine 2008;26:5612-5618
20. Tran C, Pitts J. Improving influenza vaccine compliance through patient education for patients with cystic fibrosis. J Pediatr Health Care 2007;21:57-61
21. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988;113:826-830 (Pubitemid 18272572)
22. Hiatt PW, Grace SC, Kozinetz CA, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999;103:619-626
23. Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 1984;311:1653-1658 (Pubitemid 15183995)
24. Garcia DF, Hiatt PW, Jewell A, et al. Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediatr Pulmonol 2007;42:66-74 (Pubitemid 46080155)
25. Giebels K, Marcotte JE, Podoba J, et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008;43:169-174 (Pubitemid 351273044)
26. McCormick J, Southern KW. A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child 2007;92:87-88 (Pubitemid 46132944)
27. Speer ME, Fernandes CJ, Boron M, Groothuis JR. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 2008;27:559-561
28. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007;368:652-665 (Pubitemid 46527610)
29. AstraZeneca Company data